| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphedema | 46 | 2023 | 534 | 16.070 |
Why?
|
| Breast Neoplasms | 189 | 2023 | 20827 | 9.810 |
Why?
|
| Mastectomy | 45 | 2022 | 1793 | 5.080 |
Why?
|
| Mastectomy, Segmental | 45 | 2023 | 956 | 3.990 |
Why?
|
| Radiotherapy, Conformal | 19 | 2017 | 548 | 3.010 |
Why?
|
| Lymphatic Irradiation | 14 | 2018 | 103 | 2.920 |
Why?
|
| Arm | 11 | 2021 | 588 | 2.600 |
Why?
|
| Mammaplasty | 10 | 2022 | 1204 | 2.410 |
Why?
|
| Lymph Node Excision | 27 | 2023 | 1262 | 2.340 |
Why?
|
| Neoplasm Recurrence, Local | 46 | 2023 | 9239 | 2.170 |
Why?
|
| Radiotherapy, Adjuvant | 30 | 2023 | 1770 | 1.950 |
Why?
|
| Axilla | 17 | 2023 | 597 | 1.780 |
Why?
|
| Breast Implantation | 3 | 2022 | 218 | 1.710 |
Why?
|
| Sentinel Lymph Node Biopsy | 13 | 2023 | 710 | 1.600 |
Why?
|
| Lymph Nodes | 15 | 2022 | 3476 | 1.560 |
Why?
|
| Carcinoma, Ductal, Breast | 13 | 2016 | 1100 | 1.510 |
Why?
|
| Breast | 18 | 2019 | 1970 | 1.460 |
Why?
|
| Radiotherapy Dosage | 35 | 2019 | 2879 | 1.460 |
Why?
|
| Breast Implants | 4 | 2022 | 387 | 1.450 |
Why?
|
| Tissue Expansion Devices | 5 | 2022 | 156 | 1.350 |
Why?
|
| Nomograms | 4 | 2022 | 228 | 1.330 |
Why?
|
| Postoperative Complications | 13 | 2022 | 15281 | 1.170 |
Why?
|
| Female | 197 | 2023 | 380020 | 1.110 |
Why?
|
| Photons | 10 | 2019 | 588 | 1.050 |
Why?
|
| Upper Extremity | 4 | 2021 | 647 | 1.020 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 8 | 2023 | 948 | 1.010 |
Why?
|
| Lymphatic Metastasis | 23 | 2023 | 2924 | 1.000 |
Why?
|
| Thoracic Wall | 4 | 2019 | 203 | 0.990 |
Why?
|
| Radiotherapy | 12 | 2020 | 1533 | 0.970 |
Why?
|
| Cellulitis | 2 | 2016 | 206 | 0.960 |
Why?
|
| Radiation Tolerance | 19 | 2014 | 486 | 0.900 |
Why?
|
| Neoplasms, Radiation-Induced | 5 | 2014 | 547 | 0.890 |
Why?
|
| Fat Necrosis | 5 | 2020 | 58 | 0.890 |
Why?
|
| Humans | 233 | 2023 | 743811 | 0.850 |
Why?
|
| Middle Aged | 114 | 2023 | 213241 | 0.830 |
Why?
|
| Carcinoma, Lobular | 6 | 2013 | 484 | 0.820 |
Why?
|
| Neoplasm, Residual | 4 | 2015 | 973 | 0.790 |
Why?
|
| Combined Modality Therapy | 26 | 2022 | 8637 | 0.770 |
Why?
|
| Neoplasm Staging | 36 | 2022 | 11036 | 0.750 |
Why?
|
| Hodgkin Disease | 4 | 2009 | 1415 | 0.750 |
Why?
|
| Aged | 91 | 2023 | 163178 | 0.740 |
Why?
|
| Contracture | 1 | 2022 | 223 | 0.710 |
Why?
|
| Brachytherapy | 9 | 2016 | 1247 | 0.700 |
Why?
|
| Aged, 80 and over | 46 | 2022 | 57744 | 0.700 |
Why?
|
| CREST Syndrome | 1 | 2019 | 6 | 0.700 |
Why?
|
| Neoadjuvant Therapy | 8 | 2020 | 2727 | 0.700 |
Why?
|
| Organs at Risk | 6 | 2018 | 346 | 0.680 |
Why?
|
| Adult | 93 | 2022 | 213889 | 0.650 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 12 | 2019 | 1624 | 0.640 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 19 | 2018 | 11524 | 0.630 |
Why?
|
| Radiation Injuries | 7 | 2016 | 1180 | 0.630 |
Why?
|
| Prospective Studies | 32 | 2023 | 53250 | 0.620 |
Why?
|
| Chemotherapy, Adjuvant | 15 | 2020 | 3480 | 0.610 |
Why?
|
| Dielectric Spectroscopy | 2 | 2020 | 32 | 0.610 |
Why?
|
| Receptor, erbB-2 | 11 | 2018 | 2418 | 0.600 |
Why?
|
| Anthropometry | 2 | 2020 | 1348 | 0.590 |
Why?
|
| Radiodermatitis | 2 | 2014 | 60 | 0.560 |
Why?
|
| Tumor Burden | 11 | 2017 | 1917 | 0.540 |
Why?
|
| Patient Selection | 6 | 2016 | 4210 | 0.520 |
Why?
|
| Skin | 5 | 2019 | 4372 | 0.510 |
Why?
|
| Incidence | 14 | 2022 | 20948 | 0.510 |
Why?
|
| Health Care Surveys | 4 | 2006 | 2453 | 0.500 |
Why?
|
| Follow-Up Studies | 34 | 2023 | 39001 | 0.490 |
Why?
|
| Heart | 8 | 2017 | 4460 | 0.480 |
Why?
|
| Spectrum Analysis | 3 | 2021 | 454 | 0.480 |
Why?
|
| Edema | 1 | 2018 | 789 | 0.470 |
Why?
|
| Tamoxifen | 5 | 2022 | 981 | 0.460 |
Why?
|
| Radiation Pneumonitis | 4 | 2013 | 104 | 0.450 |
Why?
|
| Radiotherapy, High-Energy | 4 | 2012 | 228 | 0.450 |
Why?
|
| Hand | 1 | 2018 | 884 | 0.430 |
Why?
|
| Glioblastoma | 16 | 2006 | 3480 | 0.430 |
Why?
|
| Proportional Hazards Models | 12 | 2018 | 12354 | 0.430 |
Why?
|
| Carcinoma in Situ | 5 | 2013 | 805 | 0.430 |
Why?
|
| Radiation Oncology | 5 | 2023 | 555 | 0.430 |
Why?
|
| Forecasting | 1 | 2022 | 2950 | 0.430 |
Why?
|
| Receptors, Estrogen | 11 | 2016 | 2190 | 0.430 |
Why?
|
| Necrosis | 4 | 2022 | 1642 | 0.420 |
Why?
|
| Risk Factors | 28 | 2020 | 72252 | 0.410 |
Why?
|
| Receptors, Progesterone | 7 | 2014 | 1098 | 0.400 |
Why?
|
| Risk Assessment | 7 | 2023 | 23327 | 0.390 |
Why?
|
| Postoperative Period | 5 | 2019 | 1841 | 0.370 |
Why?
|
| Lung | 11 | 2018 | 9858 | 0.370 |
Why?
|
| Breast Diseases | 1 | 2014 | 443 | 0.370 |
Why?
|
| Paclitaxel | 5 | 2013 | 1705 | 0.370 |
Why?
|
| Protons | 3 | 2022 | 1129 | 0.370 |
Why?
|
| Temperature | 1 | 2016 | 2202 | 0.360 |
Why?
|
| Retrospective Studies | 39 | 2022 | 77410 | 0.360 |
Why?
|
| Seroma | 2 | 2020 | 71 | 0.350 |
Why?
|
| Treatment Outcome | 32 | 2022 | 63042 | 0.340 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2015 | 806 | 0.340 |
Why?
|
| Tumor Cells, Cultured | 19 | 2001 | 6311 | 0.330 |
Why?
|
| Young Adult | 23 | 2022 | 56392 | 0.330 |
Why?
|
| Disease-Free Survival | 9 | 2016 | 6895 | 0.330 |
Why?
|
| Breast Neoplasms, Male | 4 | 2013 | 210 | 0.330 |
Why?
|
| Neoplasms, Experimental | 5 | 2001 | 1272 | 0.320 |
Why?
|
| Analysis of Variance | 9 | 2015 | 6356 | 0.320 |
Why?
|
| Collagen Diseases | 1 | 2007 | 34 | 0.310 |
Why?
|
| Antineoplastic Agents, Hormonal | 3 | 2022 | 1523 | 0.310 |
Why?
|
| Organ Size | 4 | 2020 | 2241 | 0.300 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 2727 | 0.300 |
Why?
|
| Neoplasm Transplantation | 9 | 2001 | 2085 | 0.300 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2016 | 6539 | 0.300 |
Why?
|
| Body Weight | 4 | 2013 | 4670 | 0.290 |
Why?
|
| Radiobiology | 2 | 2020 | 85 | 0.290 |
Why?
|
| Multivariate Analysis | 6 | 2019 | 12243 | 0.280 |
Why?
|
| Early Detection of Cancer | 5 | 2023 | 3089 | 0.280 |
Why?
|
| Prognosis | 25 | 2018 | 29052 | 0.280 |
Why?
|
| Neoplasms, Second Primary | 3 | 2018 | 1063 | 0.280 |
Why?
|
| Mastectomy, Modified Radical | 3 | 2015 | 62 | 0.270 |
Why?
|
| Survivors | 1 | 2016 | 2291 | 0.270 |
Why?
|
| Immobilization | 1 | 2007 | 236 | 0.270 |
Why?
|
| Fear | 1 | 2014 | 1438 | 0.270 |
Why?
|
| Health Behavior | 1 | 2017 | 2634 | 0.270 |
Why?
|
| Body Mass Index | 5 | 2014 | 12718 | 0.260 |
Why?
|
| Postoperative Care | 4 | 2019 | 1485 | 0.260 |
Why?
|
| Topotecan | 2 | 2006 | 137 | 0.260 |
Why?
|
| Transplantation, Heterologous | 12 | 2006 | 2378 | 0.260 |
Why?
|
| Attitude to Health | 1 | 2014 | 2052 | 0.260 |
Why?
|
| Mammography | 5 | 2018 | 2475 | 0.250 |
Why?
|
| Time Factors | 16 | 2019 | 40038 | 0.240 |
Why?
|
| Genetic Testing | 2 | 2022 | 3439 | 0.240 |
Why?
|
| Radiography | 7 | 2013 | 7010 | 0.240 |
Why?
|
| Pneumonia | 2 | 2009 | 2133 | 0.240 |
Why?
|
| Cohort Studies | 10 | 2021 | 40545 | 0.240 |
Why?
|
| Antineoplastic Agents | 7 | 2019 | 13691 | 0.230 |
Why?
|
| Decision Support Techniques | 3 | 2010 | 1956 | 0.220 |
Why?
|
| Fibrosarcoma | 3 | 1993 | 345 | 0.220 |
Why?
|
| Radiation-Sensitizing Agents | 4 | 2005 | 358 | 0.220 |
Why?
|
| Doxorubicin | 8 | 2013 | 2234 | 0.220 |
Why?
|
| Preoperative Period | 2 | 2016 | 550 | 0.220 |
Why?
|
| Risk | 5 | 2018 | 9677 | 0.220 |
Why?
|
| Telangiectasis | 3 | 2014 | 76 | 0.210 |
Why?
|
| Dose-Response Relationship, Radiation | 11 | 2007 | 876 | 0.210 |
Why?
|
| Carcinoma, Ductal | 2 | 2016 | 101 | 0.210 |
Why?
|
| Reference Standards | 2 | 2020 | 1023 | 0.210 |
Why?
|
| Health Expenditures | 1 | 2015 | 2348 | 0.210 |
Why?
|
| Quality of Life | 7 | 2021 | 12788 | 0.200 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2005 | 623 | 0.190 |
Why?
|
| Radiation Dosage | 5 | 2023 | 1928 | 0.190 |
Why?
|
| Feasibility Studies | 6 | 2019 | 5078 | 0.190 |
Why?
|
| Blood Pressure | 1 | 2016 | 8551 | 0.190 |
Why?
|
| Implant Capsular Contracture | 1 | 2020 | 22 | 0.190 |
Why?
|
| Survival Rate | 12 | 2016 | 12786 | 0.190 |
Why?
|
| Nipples | 2 | 2015 | 219 | 0.180 |
Why?
|
| Neoplasms | 6 | 2022 | 21675 | 0.170 |
Why?
|
| Supine Position | 2 | 2012 | 205 | 0.170 |
Why?
|
| Vascular Diseases | 1 | 2007 | 1161 | 0.170 |
Why?
|
| Carcinoma, Small Cell | 1 | 2001 | 420 | 0.170 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2022 | 17439 | 0.170 |
Why?
|
| Tattooing | 1 | 2019 | 58 | 0.160 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2020 | 151 | 0.160 |
Why?
|
| Rib Fractures | 1 | 2020 | 131 | 0.160 |
Why?
|
| Sarcoma | 10 | 1996 | 1898 | 0.160 |
Why?
|
| Europe | 4 | 2006 | 3336 | 0.160 |
Why?
|
| Nanoparticles | 1 | 2009 | 1898 | 0.160 |
Why?
|
| Neoplasm Seeding | 1 | 2018 | 87 | 0.150 |
Why?
|
| Disease Progression | 5 | 2020 | 13273 | 0.150 |
Why?
|
| Esthetics | 2 | 2011 | 305 | 0.150 |
Why?
|
| Neoplasm Invasiveness | 7 | 2012 | 3617 | 0.150 |
Why?
|
| Critical Pathways | 1 | 2021 | 476 | 0.150 |
Why?
|
| Internet | 1 | 2010 | 3058 | 0.150 |
Why?
|
| Practice Guidelines as Topic | 5 | 2020 | 7270 | 0.150 |
Why?
|
| Epidemiologic Studies | 1 | 2020 | 676 | 0.150 |
Why?
|
| Surgical Flaps | 3 | 2020 | 1629 | 0.150 |
Why?
|
| Adenocarcinoma | 5 | 2005 | 6363 | 0.140 |
Why?
|
| Carcinoma | 4 | 2021 | 2375 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2019 | 323 | 0.140 |
Why?
|
| Costs and Cost Analysis | 3 | 2017 | 1680 | 0.140 |
Why?
|
| Patient Satisfaction | 5 | 2014 | 3391 | 0.140 |
Why?
|
| Mice, Nude | 11 | 2006 | 3680 | 0.140 |
Why?
|
| Treatment Failure | 3 | 2013 | 2617 | 0.140 |
Why?
|
| Mice, SCID | 8 | 2014 | 2718 | 0.140 |
Why?
|
| Models, Biological | 2 | 2010 | 9582 | 0.140 |
Why?
|
| Reproducibility of Results | 7 | 2016 | 19894 | 0.140 |
Why?
|
| Patients | 1 | 2022 | 899 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2019 | 539 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2020 | 9944 | 0.130 |
Why?
|
| Radiotherapy, Computer-Assisted | 2 | 2012 | 94 | 0.130 |
Why?
|
| Health Care Costs | 3 | 2017 | 3207 | 0.130 |
Why?
|
| Genital Neoplasms, Female | 1 | 2020 | 523 | 0.130 |
Why?
|
| Punctures | 1 | 2016 | 374 | 0.130 |
Why?
|
| Data Mining | 2 | 2018 | 537 | 0.130 |
Why?
|
| Phlebotomy | 1 | 2015 | 141 | 0.130 |
Why?
|
| Age Factors | 9 | 2017 | 18355 | 0.120 |
Why?
|
| United States | 10 | 2023 | 69859 | 0.120 |
Why?
|
| Cisplatin | 1 | 2021 | 1662 | 0.120 |
Why?
|
| Iridium Radioisotopes | 4 | 2003 | 26 | 0.120 |
Why?
|
| Tumor Microenvironment | 2 | 2023 | 3583 | 0.120 |
Why?
|
| Taxoids | 2 | 2015 | 666 | 0.120 |
Why?
|
| Arm Injuries | 1 | 2015 | 160 | 0.120 |
Why?
|
| Hematoma | 1 | 2019 | 758 | 0.120 |
Why?
|
| Antineoplastic Protocols | 1 | 2014 | 50 | 0.120 |
Why?
|
| Physical Therapy Modalities | 1 | 2018 | 549 | 0.120 |
Why?
|
| Rare Diseases | 2 | 2011 | 552 | 0.120 |
Why?
|
| Regression Analysis | 2 | 2015 | 6457 | 0.120 |
Why?
|
| Prosthesis Failure | 1 | 2019 | 1203 | 0.120 |
Why?
|
| Keratin-19 | 1 | 2013 | 33 | 0.110 |
Why?
|
| Cicatrix | 1 | 2019 | 763 | 0.110 |
Why?
|
| Transforming Growth Factor beta | 1 | 2021 | 2006 | 0.110 |
Why?
|
| Cyclophosphamide | 5 | 2012 | 2241 | 0.110 |
Why?
|
| Imaging, Three-Dimensional | 5 | 2012 | 4033 | 0.110 |
Why?
|
| Predictive Value of Tests | 4 | 2016 | 15067 | 0.110 |
Why?
|
| Infection Control | 1 | 2020 | 964 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2013 | 35409 | 0.110 |
Why?
|
| Injections | 1 | 2015 | 839 | 0.110 |
Why?
|
| Neoplasm Metastasis | 5 | 2016 | 4848 | 0.110 |
Why?
|
| Lower Extremity | 1 | 2020 | 1158 | 0.110 |
Why?
|
| Massachusetts | 2 | 2020 | 8660 | 0.110 |
Why?
|
| Evidence-Based Practice | 1 | 2017 | 500 | 0.110 |
Why?
|
| Electric Impedance | 1 | 2016 | 729 | 0.100 |
Why?
|
| Blood Vessels | 1 | 2018 | 1124 | 0.100 |
Why?
|
| Skin Pigmentation | 1 | 2014 | 282 | 0.100 |
Why?
|
| DNA Repair | 2 | 2009 | 2045 | 0.100 |
Why?
|
| Blood Pressure Determination | 1 | 2015 | 633 | 0.100 |
Why?
|
| Survival Analysis | 8 | 2017 | 10251 | 0.100 |
Why?
|
| Relative Biological Effectiveness | 1 | 2013 | 323 | 0.100 |
Why?
|
| Oligodendroglioma | 1 | 1993 | 279 | 0.100 |
Why?
|
| Statistics, Nonparametric | 3 | 2008 | 2883 | 0.100 |
Why?
|
| Immunoenzyme Techniques | 1 | 2014 | 1799 | 0.090 |
Why?
|
| Nitroimidazoles | 1 | 1991 | 106 | 0.090 |
Why?
|
| Vaccination | 1 | 2023 | 3275 | 0.090 |
Why?
|
| Drainage | 1 | 2016 | 1142 | 0.090 |
Why?
|
| Surgical Wound Infection | 1 | 2020 | 1539 | 0.090 |
Why?
|
| Preventive Medicine | 1 | 2012 | 263 | 0.090 |
Why?
|
| Mass Screening | 3 | 2020 | 5251 | 0.090 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2018 | 933 | 0.090 |
Why?
|
| Health Surveys | 1 | 2020 | 4036 | 0.090 |
Why?
|
| Electronic Health Records | 2 | 2018 | 4467 | 0.090 |
Why?
|
| Weight Loss | 1 | 2021 | 2625 | 0.090 |
Why?
|
| Photography | 1 | 2013 | 519 | 0.090 |
Why?
|
| Unnecessary Procedures | 1 | 2013 | 432 | 0.090 |
Why?
|
| Natural Language Processing | 1 | 2018 | 1041 | 0.090 |
Why?
|
| Patient Positioning | 1 | 2012 | 324 | 0.090 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2019 | 2110 | 0.090 |
Why?
|
| Fibrosis | 3 | 2012 | 2030 | 0.090 |
Why?
|
| British Columbia | 1 | 2010 | 244 | 0.090 |
Why?
|
| Sarcoma, Kaposi | 2 | 1990 | 370 | 0.080 |
Why?
|
| Procarbazine | 1 | 2008 | 181 | 0.080 |
Why?
|
| Mechlorethamine | 1 | 2008 | 136 | 0.080 |
Why?
|
| Quality-Adjusted Life Years | 3 | 2016 | 1683 | 0.080 |
Why?
|
| Infrared Rays | 1 | 2010 | 249 | 0.080 |
Why?
|
| Electrons | 2 | 2010 | 268 | 0.080 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2011 | 252 | 0.080 |
Why?
|
| Sensitivity and Specificity | 3 | 2016 | 14714 | 0.080 |
Why?
|
| DNA, Neoplasm | 2 | 1993 | 1758 | 0.080 |
Why?
|
| Medical Oncology | 1 | 2020 | 2267 | 0.080 |
Why?
|
| Ferrosoferric Oxide | 1 | 2009 | 358 | 0.080 |
Why?
|
| Pharyngeal Neoplasms | 1 | 1988 | 117 | 0.080 |
Why?
|
| Drug Administration Schedule | 5 | 2012 | 4931 | 0.080 |
Why?
|
| Astrocytoma | 1 | 1993 | 790 | 0.080 |
Why?
|
| Societies, Medical | 1 | 2020 | 3740 | 0.080 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2009 | 180 | 0.080 |
Why?
|
| Databases as Topic | 1 | 2010 | 474 | 0.080 |
Why?
|
| Workflow | 1 | 2012 | 847 | 0.080 |
Why?
|
| Ultrasonography | 3 | 2013 | 5986 | 0.080 |
Why?
|
| Magnetite Nanoparticles | 1 | 2009 | 321 | 0.080 |
Why?
|
| Bleomycin | 1 | 2008 | 512 | 0.080 |
Why?
|
| Dextrans | 1 | 2009 | 595 | 0.080 |
Why?
|
| Vacuum | 1 | 2007 | 65 | 0.070 |
Why?
|
| Cell Survival | 10 | 1996 | 5881 | 0.070 |
Why?
|
| Vinblastine | 1 | 2008 | 501 | 0.070 |
Why?
|
| Splenectomy | 1 | 2008 | 394 | 0.070 |
Why?
|
| Age of Onset | 2 | 2016 | 3268 | 0.070 |
Why?
|
| Vincristine | 1 | 2008 | 1039 | 0.070 |
Why?
|
| France | 3 | 2014 | 517 | 0.070 |
Why?
|
| Tongue Neoplasms | 1 | 1988 | 180 | 0.070 |
Why?
|
| Neoplastic Stem Cells | 1 | 2014 | 1376 | 0.070 |
Why?
|
| Reoperation | 2 | 2013 | 4200 | 0.070 |
Why?
|
| Photogrammetry | 1 | 2006 | 73 | 0.070 |
Why?
|
| Heart Ventricles | 2 | 2017 | 3817 | 0.070 |
Why?
|
| Prone Position | 1 | 2007 | 194 | 0.070 |
Why?
|
| Life Style | 1 | 2017 | 3833 | 0.070 |
Why?
|
| Epidemiologic Methods | 1 | 2011 | 1364 | 0.070 |
Why?
|
| Dacarbazine | 1 | 2008 | 566 | 0.070 |
Why?
|
| Cost-Benefit Analysis | 3 | 2016 | 5388 | 0.070 |
Why?
|
| Fatigue | 1 | 2013 | 1530 | 0.070 |
Why?
|
| Activities of Daily Living | 1 | 2015 | 2419 | 0.070 |
Why?
|
| Mice | 20 | 2023 | 81154 | 0.070 |
Why?
|
| Lymphoma, Follicular | 1 | 2009 | 435 | 0.060 |
Why?
|
| Matched-Pair Analysis | 1 | 2005 | 288 | 0.060 |
Why?
|
| Tumor Stem Cell Assay | 4 | 1997 | 118 | 0.060 |
Why?
|
| Case-Control Studies | 3 | 2009 | 21733 | 0.060 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2016 | 2074 | 0.060 |
Why?
|
| Palpation | 1 | 2005 | 167 | 0.060 |
Why?
|
| Motor Activity | 1 | 2015 | 2714 | 0.060 |
Why?
|
| Radionuclide Imaging | 1 | 2008 | 2034 | 0.060 |
Why?
|
| Patient Education as Topic | 1 | 2014 | 2278 | 0.060 |
Why?
|
| Disease Models, Animal | 2 | 2023 | 18027 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 6 | 2018 | 4033 | 0.060 |
Why?
|
| Scleroderma, Systemic | 1 | 2007 | 323 | 0.060 |
Why?
|
| Prednisone | 1 | 2008 | 1574 | 0.060 |
Why?
|
| Pandemics | 2 | 2023 | 8385 | 0.060 |
Why?
|
| Extracellular Fluid | 1 | 2005 | 167 | 0.060 |
Why?
|
| Markov Chains | 3 | 2016 | 968 | 0.060 |
Why?
|
| Movement | 2 | 2008 | 1471 | 0.060 |
Why?
|
| Whole-Body Irradiation | 2 | 1996 | 449 | 0.060 |
Why?
|
| Echocardiography | 1 | 2016 | 5096 | 0.060 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 1990 | 2232 | 0.060 |
Why?
|
| Functional Laterality | 1 | 2010 | 2280 | 0.060 |
Why?
|
| DNA Damage | 1 | 1993 | 2429 | 0.060 |
Why?
|
| Coronary Vessels | 1 | 2014 | 3106 | 0.050 |
Why?
|
| Melphalan | 1 | 2004 | 431 | 0.050 |
Why?
|
| Colonic Neoplasms | 4 | 1996 | 2542 | 0.050 |
Why?
|
| BRCA1 Protein | 1 | 2009 | 1148 | 0.050 |
Why?
|
| Fluorouracil | 2 | 2004 | 1619 | 0.050 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 1988 | 477 | 0.050 |
Why?
|
| Brain Neoplasms | 4 | 2012 | 8856 | 0.050 |
Why?
|
| Rectal Neoplasms | 1 | 1991 | 1205 | 0.050 |
Why?
|
| Self Report | 1 | 2013 | 3550 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3134 | 0.050 |
Why?
|
| Evidence-Based Medicine | 3 | 2016 | 3608 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2017 | 20121 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3241 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2006 | 3503 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2006 | 1676 | 0.050 |
Why?
|
| Cerebellar Neoplasms | 1 | 2006 | 587 | 0.050 |
Why?
|
| Specific Pathogen-Free Organisms | 3 | 1995 | 226 | 0.050 |
Why?
|
| Soft Tissue Neoplasms | 3 | 1996 | 1363 | 0.050 |
Why?
|
| Animals | 21 | 2023 | 168660 | 0.050 |
Why?
|
| Species Specificity | 2 | 1996 | 2480 | 0.050 |
Why?
|
| Culture | 1 | 2004 | 632 | 0.050 |
Why?
|
| Confidence Intervals | 1 | 2006 | 2971 | 0.050 |
Why?
|
| ROC Curve | 1 | 2008 | 3527 | 0.050 |
Why?
|
| Erythema | 2 | 2012 | 257 | 0.050 |
Why?
|
| Biopsy, Needle | 1 | 2005 | 1639 | 0.040 |
Why?
|
| Canada | 1 | 2005 | 2064 | 0.040 |
Why?
|
| Probability | 1 | 2005 | 2505 | 0.040 |
Why?
|
| Calcinosis | 1 | 2008 | 1495 | 0.040 |
Why?
|
| Bipolar Disorder | 1 | 2016 | 5027 | 0.040 |
Why?
|
| Uterine Neoplasms | 1 | 1988 | 1513 | 0.040 |
Why?
|
| Lung Neoplasms | 2 | 2016 | 13112 | 0.040 |
Why?
|
| Lymphoma | 1 | 2008 | 1875 | 0.040 |
Why?
|
| Genetic Counseling | 1 | 2022 | 600 | 0.040 |
Why?
|
| Statistics as Topic | 1 | 2005 | 2369 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2021 | 892 | 0.040 |
Why?
|
| Oxygen Consumption | 1 | 2005 | 1869 | 0.040 |
Why?
|
| Schizophrenia | 1 | 2017 | 6865 | 0.040 |
Why?
|
| Gene Fusion | 1 | 2021 | 371 | 0.040 |
Why?
|
| Phenotype | 1 | 2016 | 16361 | 0.040 |
Why?
|
| Methotrexate | 1 | 2004 | 1726 | 0.040 |
Why?
|
| Neuroblastoma | 3 | 1995 | 1226 | 0.040 |
Why?
|
| Boston | 2 | 2008 | 9310 | 0.040 |
Why?
|
| Menopause | 1 | 2005 | 1626 | 0.040 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2020 | 337 | 0.040 |
Why?
|
| Cell Tracking | 1 | 2018 | 144 | 0.040 |
Why?
|
| Skin Neoplasms | 3 | 1995 | 5691 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2023 | 1836 | 0.030 |
Why?
|
| Child | 3 | 2009 | 77637 | 0.030 |
Why?
|
| Adolescent | 3 | 2009 | 85729 | 0.030 |
Why?
|
| Cost Allocation | 1 | 2016 | 51 | 0.030 |
Why?
|
| Radiometry | 2 | 2013 | 800 | 0.030 |
Why?
|
| Cardiotoxins | 1 | 2016 | 41 | 0.030 |
Why?
|
| Contrast Media | 1 | 2009 | 5301 | 0.030 |
Why?
|
| Surgical Instruments | 2 | 2010 | 395 | 0.030 |
Why?
|
| Glioma | 2 | 2006 | 3401 | 0.030 |
Why?
|
| Primary Prevention | 1 | 2023 | 1167 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2023 | 2077 | 0.030 |
Why?
|
| Isotretinoin | 1 | 1996 | 114 | 0.030 |
Why?
|
| Models, Econometric | 1 | 2016 | 218 | 0.030 |
Why?
|
| Elastic Modulus | 1 | 2016 | 214 | 0.030 |
Why?
|
| Luminescent Proteins | 1 | 2018 | 853 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2020 | 1254 | 0.030 |
Why?
|
| Transfection | 2 | 2014 | 5892 | 0.030 |
Why?
|
| Cytosol | 1 | 2018 | 901 | 0.030 |
Why?
|
| Melanoma, Experimental | 1 | 2018 | 560 | 0.030 |
Why?
|
| Indomethacin | 1 | 1995 | 332 | 0.030 |
Why?
|
| Belgium | 1 | 2014 | 103 | 0.030 |
Why?
|
| Stroke Volume | 2 | 2018 | 5002 | 0.030 |
Why?
|
| Anthracyclines | 1 | 2016 | 288 | 0.030 |
Why?
|
| Radiation Genetics | 1 | 1993 | 16 | 0.030 |
Why?
|
| Comorbidity | 1 | 2008 | 10380 | 0.030 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2021 | 1660 | 0.030 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2021 | 1581 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2001 | 3547 | 0.030 |
Why?
|
| Random Allocation | 2 | 2014 | 2429 | 0.030 |
Why?
|
| Logistic Models | 1 | 2008 | 13404 | 0.030 |
Why?
|
| Melanoma | 1 | 1991 | 5508 | 0.030 |
Why?
|
| Sarcoma, Experimental | 1 | 1992 | 128 | 0.030 |
Why?
|
| Male | 18 | 2017 | 349776 | 0.030 |
Why?
|
| Etanidazole | 1 | 1991 | 26 | 0.030 |
Why?
|
| Databases, Factual | 2 | 2018 | 7729 | 0.030 |
Why?
|
| Lymphangiosarcoma | 1 | 1991 | 13 | 0.030 |
Why?
|
| Interferon-alpha | 1 | 1996 | 895 | 0.030 |
Why?
|
| Tonsillar Neoplasms | 1 | 1992 | 51 | 0.030 |
Why?
|
| Head and Neck Neoplasms | 2 | 1996 | 2736 | 0.020 |
Why?
|
| Biopsy | 3 | 2009 | 6750 | 0.020 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2014 | 520 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2005 | 11360 | 0.020 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2016 | 388 | 0.020 |
Why?
|
| Cell Line | 3 | 1996 | 15993 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2005 | 3839 | 0.020 |
Why?
|
| Patient Compliance | 2 | 2016 | 2683 | 0.020 |
Why?
|
| Clinical Trials as Topic | 2 | 2020 | 7908 | 0.020 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 1991 | 109 | 0.020 |
Why?
|
| Catheterization | 1 | 2016 | 1469 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2023 | 4152 | 0.020 |
Why?
|
| Respiration | 2 | 2008 | 1653 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2018 | 16674 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2014 | 1876 | 0.020 |
Why?
|
| Oxygen | 1 | 2001 | 4189 | 0.020 |
Why?
|
| Life Expectancy | 1 | 2016 | 1184 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2001 | 10940 | 0.020 |
Why?
|
| Cesium Radioisotopes | 1 | 1988 | 36 | 0.020 |
Why?
|
| Rad51 Recombinase | 1 | 2009 | 189 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2018 | 6380 | 0.020 |
Why?
|
| Frozen Sections | 1 | 2009 | 155 | 0.020 |
Why?
|
| Fanconi Anemia Complementation Group D2 Protein | 1 | 2009 | 148 | 0.020 |
Why?
|
| Radiation, Ionizing | 1 | 2009 | 258 | 0.020 |
Why?
|
| Poverty | 1 | 2020 | 2660 | 0.020 |
Why?
|
| Salvage Therapy | 1 | 2015 | 1275 | 0.020 |
Why?
|
| Xanthenes | 1 | 2007 | 73 | 0.020 |
Why?
|
| Estrogen Antagonists | 1 | 2008 | 151 | 0.020 |
Why?
|
| Genomics | 1 | 2023 | 5714 | 0.020 |
Why?
|
| Developing Countries | 1 | 2020 | 2815 | 0.020 |
Why?
|
| Stromal Cells | 1 | 1993 | 1356 | 0.020 |
Why?
|
| Drug Synergism | 1 | 1991 | 1794 | 0.020 |
Why?
|
| Particle Accelerators | 1 | 2008 | 173 | 0.020 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2016 | 1164 | 0.020 |
Why?
|
| Appointments and Schedules | 1 | 2010 | 417 | 0.020 |
Why?
|
| Heart Diseases | 1 | 1999 | 2789 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2009 | 23398 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2014 | 2736 | 0.020 |
Why?
|
| Ventricular Function, Left | 1 | 2018 | 3660 | 0.020 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2010 | 446 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2023 | 10179 | 0.020 |
Why?
|
| Cell Movement | 1 | 2018 | 5216 | 0.020 |
Why?
|
| Oncogenes | 1 | 1991 | 1265 | 0.020 |
Why?
|
| Disease Management | 1 | 2016 | 2459 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2016 | 2922 | 0.020 |
Why?
|
| Recurrence | 1 | 2017 | 8337 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2008 | 40964 | 0.020 |
Why?
|
| Osteosarcoma | 1 | 1991 | 881 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2018 | 9848 | 0.020 |
Why?
|
| Calibration | 1 | 2008 | 816 | 0.020 |
Why?
|
| Cell Division | 3 | 1997 | 4568 | 0.020 |
Why?
|
| Skin Diseases | 1 | 2012 | 1066 | 0.010 |
Why?
|
| Antipsychotic Agents | 1 | 2017 | 3057 | 0.010 |
Why?
|
| Depressive Disorder | 1 | 2016 | 3744 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1995 | 4422 | 0.010 |
Why?
|
| Lethal Dose 50 | 2 | 1993 | 77 | 0.010 |
Why?
|
| Life Tables | 1 | 2003 | 363 | 0.010 |
Why?
|
| Observer Variation | 1 | 2009 | 2592 | 0.010 |
Why?
|
| Nitriles | 1 | 2007 | 953 | 0.010 |
Why?
|
| Rectus Abdominis | 1 | 2002 | 97 | 0.010 |
Why?
|
| Inflammation | 1 | 2001 | 10629 | 0.010 |
Why?
|
| Registries | 1 | 2017 | 8090 | 0.010 |
Why?
|
| Healthcare Disparities | 1 | 2017 | 3155 | 0.010 |
Why?
|
| Mice, Inbred C3H | 2 | 1993 | 964 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1991 | 2942 | 0.010 |
Why?
|
| Postmenopause | 1 | 2010 | 2458 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 12954 | 0.010 |
Why?
|
| Coronary Disease | 1 | 2016 | 6078 | 0.010 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2016 | 3655 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2018 | 21824 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 13980 | 0.010 |
Why?
|
| Equipment Design | 1 | 2008 | 3574 | 0.010 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2003 | 604 | 0.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2016 | 5230 | 0.010 |
Why?
|
| Algorithms | 1 | 2018 | 13869 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2010 | 8316 | 0.010 |
Why?
|
| Pain | 1 | 2012 | 4987 | 0.010 |
Why?
|
| Hospitalization | 1 | 2016 | 10259 | 0.010 |
Why?
|
| Recombinant Proteins | 2 | 1996 | 6620 | 0.010 |
Why?
|
| Hindlimb | 1 | 1996 | 503 | 0.010 |
Why?
|
| Mutation | 1 | 2017 | 29777 | 0.010 |
Why?
|
| Mortality | 1 | 2003 | 2862 | 0.010 |
Why?
|
| Flow Cytometry | 2 | 1993 | 5973 | 0.010 |
Why?
|
| Software | 1 | 2006 | 4440 | 0.010 |
Why?
|
| Rats, Inbred Strains | 1 | 1991 | 2184 | 0.010 |
Why?
|
| Kinetics | 1 | 1996 | 6476 | 0.000 |
Why?
|
| Opportunistic Infections | 1 | 1990 | 389 | 0.000 |
Why?
|
| Cells, Cultured | 2 | 1992 | 19232 | 0.000 |
Why?
|
| Linear Models | 1 | 1996 | 5952 | 0.000 |
Why?
|
| Embryo, Mammalian | 1 | 1991 | 1702 | 0.000 |
Why?
|
| Cell Cycle | 1 | 1991 | 2963 | 0.000 |
Why?
|
| Fibroblasts | 1 | 1992 | 4162 | 0.000 |
Why?
|
| Endothelium, Vascular | 1 | 1993 | 4459 | 0.000 |
Why?
|
| Rats | 1 | 1991 | 24250 | 0.000 |
Why?
|